Reviva's Q2 2026: Cash Runway to July 2027, but Going Concern Lingers
RVPH sits 76% above its 52-week low of $0.262 on light trading volume (0.1× avg).
Summary
Reviva Pharmaceuticals posted a narrower Q2 2026 net loss of $2.4 million and extended its cash runway to July 2027, but going concern uncertainty remains after its Nasdaq delisting.
Key Events · Earnings and Guidance · RVPH
-
Q2 Net Loss Narrows
The Q2 2026 net loss came in at $2.4 million, down from $6.1 million in Q2 2025, driven by a 62.6% reduction in R&D expenses as the OLE trial winds down.
-
Cash Runway Extended
Cash and cash equivalents totaled $19.9 million as of June 30, 2026, up from $14.4 million at year-end 2025, after raising $10 million in a March 2026 public offering and $2.5 million via ATM sales.
-
Going Concern Warning Reiterated
Management states that current cash is not sufficient for 12 months of operating needs and that substantial doubt exists regarding the company's ability to continue as a going concern.
-
Nasdaq Delisting Confirmed
Common stock was suspended from Nasdaq on May 14, 2026, and now trades on the OTCQB Venture Market under symbol RVPH.
Analysis · RVPH · Life Sciences
The Q2 2026 10-Q reveals a sharply narrower net loss of $2.4 million, down from $6.1 million a year earlier, as the Phase 3 OLE trial winds down. Cash on hand of $19.9 million, bolstered by a $10 million public offering in March 2026, is projected to fund operations into July 2027. Yet substantial doubt about the company's ability to continue as a going concern persists, and its common stock now trades on the OTCQB following a Nasdaq delisting in May 2026. The filing also details a new patent application for a novel form of brilaroxazine, with FDA feedback expected in Q4 2026, and plans to initiate the RECOVER-2 Phase 3 trial in the first half of 2027.
At the time of this filing, RVPH was trading at $0.46 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $0.26 to $17.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.